The Endocrine Society has accepted the NETest as a biomarker for microscopic liver disease (minimal residual disease) in neuroendocrine tumors for their thematic issue on Neuroendocrinology in 2019.

The data identifies that “Emerging molecular liquid biopsies (e.g., NETest) provide a substantially improved threshold for disease detection.” 

[npfButton size=“small” text=”Click here to read more” href=”https://academic.oup.com/jcem/article/104/3/867/5143222″ background-colour=”#37b8c0″ text-colour=”#ffffff”]